Aiolos Bio is a biotech company focused on developing innovative therapies for respiratory diseases and immune conditions. With a recent series A investment of $245 million, Aiolos Bio is advancing the development of a novel TSLP antibody that is phase 2-ready. Their mission is to address the treatment needs of patients with respiratory and inflammatory conditions.

Aiolos Bio: $245 Million Raised To Address Treatment Needs For Patients With Respiratory And Inflammatory Conditions #Startups #VentureCapital #AiolosBio.

With one of the higher series A rounds for 2023, the newly launched Aiolos Bio Inc. pulled in $245 million to advance its lead product, AIO ...

Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody. businesswire.com · 127 1 ...

Aiolos Bio

Find contacts at this company